Selective Signaling via Unique Ml Muscarinic Agonists

ABRAHAM FISHER, ELIAHU HELDMAN, DAVID GURWITZ, RACHEL HARING, DOV BARAK, HAIM MESHULAM, DANIELE MARCIANO, RACHEL BRANDEIS, ZIPORA PITTEL, MENAHEM SEGAL, ZVI VOGEL, YISHAI KARTON

Research output: Contribution to journalArticlepeer-review

Abstract

Rigid analogs of acetylcholine (ACh) were designed for selective actions at muscarinic receptor (mAChR) subtypes and distinct second messenger systems. AF102B, AF150, and AF151 are such rigid analogs of ACh. AF102B, AF150 and AF151 are centrally active M1 agonists. AF102B has a unique agonistic profile showing, inter alia: only part of the M1 electrophysiology of ACh and unusual binding parameters to mAChRs. AF150 and AF151 are more efficacious agonists than AP102B for M1 AChRS in rat cortex and in CHO cells stably transfected with the ml AChR subtype. Notably, the selectivity of the new ml agonists is reflected also by activation of select second messenger systems via distinct G‐proteins. These compounds reflect a new pharmacological concept, tentatively defined as ligand‐selective signaling. Thus, agonist/m1AChR complexes may activate different combinations of signaling pathways, depending on the ligand used. Rigid agonists may activate a limited repertoire of signaling systems. In various animal models for Alzheimer's disease (AD) the agonists AF102B, AF150 and AF151, exhibited positive effects on mnemomic processes and a wide safety margin. Such agonists, and especially AF102B, can be considered as a rational treatment strategy for AD.

Original languageEnglish
Pages (from-to)300-303
Number of pages4
JournalAnnals of the New York Academy of Sciences
Volume695
Issue number1
DOIs
StatePublished - Sep 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Selective Signaling via Unique Ml Muscarinic Agonists'. Together they form a unique fingerprint.

Cite this